

BIOGRAPHICAL SKETCH

David Hobson, M.S., Ph.D., DABT – Dr. Hobson has combined practical experience in conducting and directing toxicological and pharmacological research of over 30 years (academic, government and industry) as well as over 20 years of pharmaceutical and medical device discovery, development and commercialization experience. He has been consulting for twelve years. His consulting practice, LoneStar PharmTox LLC, is located in Boerne, Texas. During the past two years he has served as Secretary, for the Roundtable of Toxicology Consultants (RTC) and is currently the Vice President for the (RTC). He has presented symposia and training sessions on medical device and nanotechnology safety as well as chaired symposia at annual meetings of the American College of Toxicology, Society of Toxicology, Symposium on Advanced Wound Care,. He has patents for various applications including infection control and has authored chapters and peer reviewed manuscripts on infection control to include aspects of toxicological safety assessment for infection control products and a chapter in S. Block's seminal text on infection control. He is an experienced consultant to government and industry clients on product and technology development issues for pharmaceutical, medical device, biotechnology, nanotechnology, wound healing and tissue repair therapeutics. His former positions include Principal, H&H Scientific Services LLP, Vice President for Research and Development, Chrysalis Biotechnology, Inc.; Vice President, Medical Product Research and Development, Healthpoint, Ltd.; Director of Pharmaceutical Sciences, DPT Laboratories Ltd.; Vice President for Medical Research and Development, Research Fellow and Principal Scientist at Battelle Memorial Institute; and Director of Applied Toxicology, U.S. Naval Medical Research Institute. He is a past president and former councilor of the American College of Toxicology and has served as president of the dermal toxicology specialty section of the Society of Toxicology (SOT), councilor for the nanotechnology specialty section of SOT and membership committee chair for the Wound Healing Society. He has been intimately involved in the development and commercialization of various pharmaceutical products, including infection control products, nanoproducts, and medical devices as well as in the discovery, research and development of wound healing, burn, dermatological, orthopedic, cardiovascular, oral, ophthalmic, anti-infective and tissue repair products for human and veterinary use. His product development experience includes most aspects of pharmaceutical, medical device and cosmetic development including discovery, patenting, development, manufacturing, packaging, labeling, regulatory approval and post-approval, marketing support and litigation of various commercial pharmaceutical products and medical devices. He holds a Bachelor of Science degree from the University of Nebraska as well as Master of Science and Doctor of Philosophy degrees from Texas A&M University. He is a 30-year, diplomate of the American Board of Toxicology. His principal fields of training and expertise are in toxicology and pharmacology. Dr. Hobson is a retired U.S. Naval reserve officer with experience as a 500 bed fleet hospital executive officer and commanding officer of a Marine medical unit. He continues to serve as an advisor for various government projects and as an adjunct professor at the University of the Incarnate Word where he has taught courses in Biophysics, Radiation Biology, and Nuclear Pharmacy for ten years. He has authored or co-authored articles and book chapters on product safety, dermatotoxicology, gastrointestinal toxicology, pharmacology and toxicology study design, nanobiotechnology, nanomaterials commercialization and safety, pharmaceutical manufacturing and product formulation, as other aspects of pharmaceutical research and development.